Virtus ETF Advisers’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-5,242
| Closed | -$61.1K | – | 529 |
|
|
2024
Q4 | $61.1K | Buy |
5,242
+1,692
| +48% | +$19.7K | 0.03% | 445 |
|
|
2024
Q3 | $73K | Buy |
3,550
+63
| +2% | +$1.3K | 0.03% | 423 |
|
|
2024
Q2 | $78K | Buy |
3,487
+768
| +28% | +$17.2K | 0.04% | 414 |
|
|
2024
Q1 | $74.8K | Sell |
2,719
-187
| -6% | -$5.14K | 0.04% | 401 |
|
|
2023
Q4 | $88.6K | Buy |
2,906
+714
| +33% | +$21.8K | 0.06% | 407 |
|
|
2023
Q3 | $69.3K | Sell |
2,192
-214
| -9% | -$6.77K | 0.04% | 388 |
|
|
2023
Q2 | $98.1K | Sell |
2,406
-204
| -8% | -$8.32K | 0.06% | 395 |
|
|
2023
Q1 | $97.3K | Sell |
2,610
-1,000
| -28% | -$37.3K | 0.05% | 345 |
|
|
2022
Q4 | $126K | Buy |
3,610
+890
| +33% | +$31.1K | 0.07% | 403 |
|
|
2022
Q3 | $152K | Buy |
2,720
+26
| +1% | +$1.45K | 0.06% | 352 |
|
|
2022
Q2 | $139K | Buy |
2,694
+1,341
| +99% | +$69.2K | 0.05% | 331 |
|
|
2022
Q1 | $98K | Sell |
1,353
-72
| -5% | -$5.22K | 0.04% | 306 |
|
|
2021
Q4 | $168K | Sell |
1,425
-994
| -41% | -$117K | 0.06% | 296 |
|
|
2021
Q3 | $325K | Sell |
2,419
-123
| -5% | -$16.5K | 0.14% | 191 |
|
|
2021
Q2 | $412K | Sell |
2,542
-3,219
| -56% | -$522K | 0.17% | 190 |
|
|
2021
Q1 | $462K | Buy |
5,761
+99
| +2% | +$7.94K | 0.2% | 159 |
|
|
2020
Q4 | $308K | Sell |
5,662
-10,265
| -64% | -$558K | 0.13% | 202 |
|
|
2020
Q3 | $317K | Sell |
15,927
-2,173
| -12% | -$43.3K | 0.17% | 208 |
|
|
2020
Q2 | $380K | Buy |
+18,100
| New | +$380K | 0.18% | 219 |
|